The latest clinical trial flop from Novavax (NASDAQ: NVAX) wasn't nearly as bad as the failure it announced in 2016, but it was still a long way from what most vaccine developers would consider a success. There's still a glimmer of hope, though, because the respiratory syncytial virus (RSV) isn't like most viruses.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,